These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 21428798)
1. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Huber JL; McBurney MW; Distefano PS; McDonagh T Future Med Chem; 2010 Dec; 2(12):1751-9. PubMed ID: 21428798 [TBL] [Abstract][Full Text] [Related]
2. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. Pacholec M; Bleasdale JE; Chrunyk B; Cunningham D; Flynn D; Garofalo RS; Griffith D; Griffor M; Loulakis P; Pabst B; Qiu X; Stockman B; Thanabal V; Varghese A; Ward J; Withka J; Ahn K J Biol Chem; 2010 Mar; 285(11):8340-51. PubMed ID: 20061378 [TBL] [Abstract][Full Text] [Related]
3. A patent review of sirtuin activators: an update. Villalba JM; de Cabo R; Alcain FJ Expert Opin Ther Pat; 2012 Apr; 22(4):355-67. PubMed ID: 22475539 [TBL] [Abstract][Full Text] [Related]
4. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. Gurt I; Artsi H; Cohen-Kfir E; Hamdani G; Ben-Shalom G; Feinstein B; El-Haj M; Dresner-Pollak R PLoS One; 2015; 10(7):e0134391. PubMed ID: 26226624 [TBL] [Abstract][Full Text] [Related]
5. AROuSing SIRT1: identification of a novel endogenous SIRT1 activator. Verdin E Mol Cell; 2007 Nov; 28(3):354-6. PubMed ID: 17996699 [TBL] [Abstract][Full Text] [Related]
6. SIRT1 upregulation protects against liver injury induced by a HFD through inhibiting CD36 and the NF‑κB pathway in mouse kupffer cells. Niu B; He K; Li P; Gong J; Zhu X; Ye S; Ou Z; Ren G Mol Med Rep; 2018 Aug; 18(2):1609-1615. PubMed ID: 29845302 [TBL] [Abstract][Full Text] [Related]
7. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes. Höppner S; Schänzer W; Thevis M Rapid Commun Mass Spectrom; 2013 Jan; 27(1):35-50. PubMed ID: 23239315 [TBL] [Abstract][Full Text] [Related]
8. Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Bugyei-Twum A; Ford C; Civitarese R; Seegobin J; Advani SL; Desjardins JF; Kabir G; Zhang Y; Mitchell M; Switzer J; Thai K; Shen V; Abadeh A; Singh KK; Billia F; Advani A; Gilbert RE; Connelly KA Cardiovasc Res; 2018 Oct; 114(12):1629-1641. PubMed ID: 29800064 [TBL] [Abstract][Full Text] [Related]
10. Novel SIRT1 activator MHY2233 improves glucose tolerance and reduces hepatic lipid accumulation in db/db mice. Kim MJ; An HJ; Kim DH; Lee B; Lee HJ; Ullah S; Kim SJ; Jeong HO; Moon KM; Lee EK; Yang J; Akter J; Chun P; Moon HR; Chung HY Bioorg Med Chem Lett; 2018 Feb; 28(4):684-688. PubMed ID: 29402742 [TBL] [Abstract][Full Text] [Related]
11. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. Smith JJ; Kenney RD; Gagne DJ; Frushour BP; Ladd W; Galonek HL; Israelian K; Song J; Razvadauskaite G; Lynch AV; Carney DP; Johnson RJ; Lavu S; Iffland A; Elliott PJ; Lambert PD; Elliston KO; Jirousek MR; Milne JC; Boss O BMC Syst Biol; 2009 Mar; 3():31. PubMed ID: 19284563 [TBL] [Abstract][Full Text] [Related]
12. SIRTUIN 1 ACTIVATOR SRT1720 PROTECTS AGAINST ORGAN INJURY INDUCED BY INTESTINAL ISCHEMIA-REPERFUSION. Hansen LW; Khader A; Yang WL; Prince JM; Nicastro JM; Coppa GF; Wang P Shock; 2016 Apr; 45(4):359-66. PubMed ID: 26263437 [TBL] [Abstract][Full Text] [Related]
13. Search for a novel SIRT1 activator: structural modification of SRT1720 and biological evaluation. Matsuya Y; Kobayashi Y; Uchida S; Itoh Y; Sawada H; Suzuki T; Miyata N; Sugimoto K; Toyooka N Bioorg Med Chem Lett; 2013 Sep; 23(17):4907-10. PubMed ID: 23876989 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. Bellet MM; Nakahata Y; Boudjelal M; Watts E; Mossakowska DE; Edwards KA; Cervantes M; Astarita G; Loh C; Ellis JL; Vlasuk GP; Sassone-Corsi P Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3333-8. PubMed ID: 23341587 [TBL] [Abstract][Full Text] [Related]
15. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Suzuki K; Hayashi R; Ichikawa T; Imanishi S; Yamada T; Inomata M; Miwa T; Matsui S; Usui I; Urakaze M; Matsuya Y; Ogawa H; Sakurai H; Saiki I; Tobe K Oncol Rep; 2012 Jun; 27(6):1726-32. PubMed ID: 22470132 [TBL] [Abstract][Full Text] [Related]
16. Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes. Höppner S; Delahaut P; Schänzer W; Thevis M J Pharm Biomed Anal; 2014 Jan; 88():649-59. PubMed ID: 24239904 [TBL] [Abstract][Full Text] [Related]
17. SIRT1 activator (SRT1720) improves the follicle reserve and prolongs the ovarian lifespan of diet-induced obesity in female mice via activating SIRT1 and suppressing mTOR signaling. Zhou XL; Xu JJ; Ni YH; Chen XC; Zhang HX; Zhang XM; Liu WJ; Luo LL; Fu YC J Ovarian Res; 2014 Oct; 7():97. PubMed ID: 25330910 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and Assay of SIRT1-Activating Compounds. Dai H; Ellis JL; Sinclair DA; Hubbard BP Methods Enzymol; 2016; 574():213-244. PubMed ID: 27423864 [TBL] [Abstract][Full Text] [Related]
19. Protective role of SIRT1 in diabetic vascular dysfunction. Orimo M; Minamino T; Miyauchi H; Tateno K; Okada S; Moriya J; Komuro I Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):889-94. PubMed ID: 19286634 [TBL] [Abstract][Full Text] [Related]
20. Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology. Robers MB; Loh C; Carlson CB; Yang H; Frey EA; Hermanson SB; Bi K Mol Biosyst; 2011 Jan; 7(1):59-66. PubMed ID: 20931131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]